<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37477841</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1534-6307</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current rheumatology reports</Title><ISOAbbreviation>Curr Rheumatol Rep</ISOAbbreviation></Journal><ArticleTitle>Systemic Lupus Erythematosus and COVID-19.</ArticleTitle><Pagination><StartPage>192</StartPage><EndPage>203</EndPage><MedlinePgn>192-203</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11926-023-01110-z</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">To describe the current state of knowledge regarding COVID-19 in patients with systemic lupus erythematosus (SLE). We focus on (i) SARS-CoV-2 vaccination uptake, immunogenicity and safety, and (ii) outcomes of COVID-19 in patients with SLE and pertinent risk factors for adverse sequelae.</AbstractText><AbstractText Label="RECENT FINDINGS">Notwithstanding the potential concern of patients about possible post-vaccination side-effects, the safety of anti-SARS-CoV-2 vaccines in patients with SLE has been undisputedly confirmed in numerous studies. Humoral immunogenicity is generally attained in SLE, although affected by the use of background immunosuppressive drugs, especially rituximab. The latter has also clearly been implicated with adverse COVID-19 outcomes in SLE, including need for hospitalization, mechanical ventilation and death. Although the wide adoption of vaccination has significantly improved COVID-19 outcomes, patients with SLE continue to pose challenges during the pandemic, mainly owing to administered immunosuppressive medications.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pappa</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1296-0693</Identifier><AffiliationInfo><Affiliation>1st Department of Propaedeutic Internal Medicine, Medical School National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panagiotopoulos</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1st Department of Propaedeutic Internal Medicine, Medical School National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7489-7776</Identifier><AffiliationInfo><Affiliation>4th Department of Internal Medicine, "Attikon" University Hospital, Medical School National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanouriakis</LastName><ForeName>Antonis</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2696-031X</Identifier><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology, "Attikon" University Hospital of Athens, Medical School National and Kapodistrian University of Athens, Athens, Greece. afanour@med.uoa.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Rheumatol Rep</MedlineTA><NlmUniqueID>100888970</NlmUniqueID><ISSNLinking>1523-3774</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>13</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37477841</ArticleId><ArticleId IdType="pmc">PMC10504107</ArticleId><ArticleId IdType="doi">10.1007/s11926-023-01110-z</ArticleId><ArticleId IdType="pii">10.1007/s11926-023-01110-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450&#x2013;452. doi: 10.1038/s41591-020-0820-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0820-9</ArticleId><ArticleId IdType="pmc">PMC7095063</ArticleId><ArticleId IdType="pubmed">32284615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020;382:727&#x2013;733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>https://covid19.who.int/. Accessed 18 Jun 2023.</Citation></Reference><Reference><Citation>Horita N, Fukumoto T. Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic. J Med Virol. 2023; 10.1002/jmv.28231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9874414</ArticleId><ArticleId IdType="pubmed">36253938</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen LE, Spiro DJ, Viboud C. Projecting the SARS-CoV-2 transition from pandemicity to endemicity: epidemiological and immunological considerations. PLoS Pathog. 2022; 10.1371/journal.ppat.1010591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246171</ArticleId><ArticleId IdType="pubmed">35771775</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway R, Grimshaw AA, Konig MF, et al. SARS &#x2013; CoV-2 Infection and COVID -19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis &amp; Rheumatology. 2022;74:766&#x2013;775. doi: 10.1002/art.42030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42030</ArticleId><ArticleId IdType="pmc">PMC9011807</ArticleId><ArticleId IdType="pubmed">34807517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011. Arthritis Care Res (Hoboken) 2015;67:1078&#x2013;1085. doi: 10.1002/acr.22575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22575</ArticleId><ArticleId IdType="pmc">PMC4516647</ArticleId><ArticleId IdType="pubmed">25732901</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017;76:2009&#x2013;2016. doi: 10.1136/annrheumdis-2017-211663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211663</ArticleId><ArticleId IdType="pubmed">28794077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia V-K, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G, Vourli G, Paraskevis D, Tektonidou MG, Sfikakis PP. All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015&#x2013;2019. RMD Open. 2021;7:e001694. doi: 10.1136/rmdopen-2021-001694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001694</ArticleId><ArticleId IdType="pmc">PMC8565571</ArticleId><ArticleId IdType="pubmed">34728554</ArticleId></ArticleIdList></Reference><Reference><Citation>Spihlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and systemic lupus erythematosus: focus on immune response and therapeutics. Front Immunol. 2020; 10.3389/fimmu.2020.589474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7661632</ArticleId><ArticleId IdType="pubmed">33193418</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Wang Y, Guga S, Wu K, et al. COVID-19 and systemic lupus erythematosus genetics: a balance between autoimmune disease risk and protection against infection. PLoS Genet. 2022; 10.1371/journal.pgen.1010253. This study demonstrates the genetic association of TYK2 between patients with severe COVID-19 and those with systemic lupus erythematosus</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9632821</ArticleId><ArticleId IdType="pubmed">36327221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Liu Z, Moncada-Velez M, et al. (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 1979; 10.1126/science.abd4570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 1979; 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Ugarte-Gil MF, Alarc&#xf3;n GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13:799&#x2013;814. doi: 10.1080/1744666X.2017.1327352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2017.1327352</ArticleId><ArticleId IdType="pubmed">28471259</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516&#x2013;527. doi: 10.1038/s41586-020-2798-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2798-3</ArticleId><ArticleId IdType="pubmed">32967006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gra&#xf1;a C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database of Systematic Reviews. 2022, 2023:CD015477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726273</ArticleId><ArticleId IdType="pubmed">36473651</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2023.</Citation></Reference><Reference><Citation>Felten R, Dubois M, Ugarte-Gil MF, et al. Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol. 2021;3:e243&#x2013;e245. doi: 10.1016/S2665-9913(21)00039-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00039-4</ArticleId><ArticleId IdType="pmc">PMC7906671</ArticleId><ArticleId IdType="pubmed">33655219</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatol. 2023;75:E1&#x2013;E16. doi: 10.1002/art.42372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42372</ArticleId><ArticleId IdType="pmc">PMC9878068</ArticleId><ArticleId IdType="pubmed">36345691</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39&#x2013;52. doi: 10.1136/annrheumdis-2019-215882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215882</ArticleId><ArticleId IdType="pubmed">31413005</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulenok T, Francois C, Mendes C, Farhi F, Alexandra J-F, Rouzaud D, Papo T, Sacre K. Improving COVID-19 vaccine coverage in patients with autoimmune and inflammatory diseases. J Rheumatol. 2022;49:118&#x2013;119. doi: 10.3899/jrheum.210534.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.210534</ArticleId><ArticleId IdType="pubmed">34654731</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YK, Lui MPK, Yam LL, Cheng CS, Tsang THT, Kwok WS, Chung HY. COVID-19 vaccination in patients with rheumatic diseases: vaccination rates, patient perspectives, and side effects. Immun Inflamm Dis. 2022;10:e589. doi: 10.1002/iid3.589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.589</ArticleId><ArticleId IdType="pmc">PMC8926511</ArticleId><ArticleId IdType="pubmed">35099852</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevet B, Figueroa-Parra G, Yang JX, Hulshizer CA, Gunderson TM, Duong SQ, Putman MS, Barbour KE, Crowson CS, Duarte-Garc&#xed;a A. COVID-19 vaccine uptake among patients with systemic lupus erythematosus in the American Midwest: the Lupus Midwest Network (LUMEN).&#xa0;J Rheumatol. 2022;49(11):1276&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9633343</ArticleId><ArticleId IdType="pubmed">35777817</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Parra G, Esquivel-Valerio JA, Santoyo-Fexas L, Moreno-Salinas A, Gamboa-Alonso CM, De Leon-Ibarra AL, Galarza-Delgado DA. Knowledge and attitudes about influenza vaccination in rheumatic diseases patients. Hum Vaccin Immunother. 2021;17:1420&#x2013;1425. doi: 10.1080/21645515.2020.1816108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1816108</ArticleId><ArticleId IdType="pmc">PMC8078649</ArticleId><ArticleId IdType="pubmed">32991221</ArticleId></ArticleIdList></Reference><Reference><Citation>Loubet P, Kern&#xe9;is S, Groh M, Loulergue P, Blanche P, Verger P, Launay O. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine. 2015;33:3703&#x2013;3708. doi: 10.1016/j.vaccine.2015.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.06.012</ArticleId><ArticleId IdType="pubmed">26073016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SYS, Yee AM, Sim JJL, Lim CC. COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance. Rheumatology. 2022; 10.1093/rheumatology/keac604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9620290</ArticleId><ArticleId IdType="pubmed">36271852</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R, Kawka L, Dubois M, Ugarte-Gil MF, Fuentes-Silva Y, Piga M, Arnaud L. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021;3:e613&#x2013;e615. doi: 10.1016/S2665-9913(21)00221-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00221-6</ArticleId><ArticleId IdType="pmc">PMC8294805</ArticleId><ArticleId IdType="pubmed">34312612</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki EFN, Borba EF, Pasoto SG, et al. Impact of distinct therapies on antibody response to &lt;scp&gt;SARS-CoV&lt;/scp&gt; -2 vaccine in systemic lupus erythematosus. Arthritis Care Res. 2022;74:562&#x2013;571. doi: 10.1002/acr.24824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24824</ArticleId><ArticleId IdType="pmc">PMC9011410</ArticleId><ArticleId IdType="pubmed">34806342</ArticleId></ArticleIdList></Reference><Reference><Citation>Heshin-Bekenstein M, Ziv A, Toplak N, et al. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatology. 2022;61:4263&#x2013;4272. doi: 10.1093/rheumatology/keac103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac103</ArticleId><ArticleId IdType="pmc">PMC9383463</ArticleId><ArticleId IdType="pubmed">35179569</ArticleId></ArticleIdList></Reference><Reference><Citation>Md Yusof MY, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, Vital EM, Emery P. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. Lancet. Rheumatol. 2023;5:e88&#x2013;e98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873269</ArticleId><ArticleId IdType="pubmed">36712951</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyon Q, Sterlin D, Miyara M, et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2022;81:575&#x2013;583. doi: 10.1136/annrheumdis-2021-221097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221097</ArticleId><ArticleId IdType="pmc">PMC8494536</ArticleId><ArticleId IdType="pubmed">34607791</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS&#x2013;CoV-2 vaccination. Arthritis and Rheumatology. 2022;74:284&#x2013;294. doi: 10.1002/art.41937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41937</ArticleId><ArticleId IdType="pmc">PMC8426963</ArticleId><ArticleId IdType="pubmed">34347939</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Cirera S, Calvet J, Berenguer-Llergo A, et al. Glucocorticoids&#x2019; treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients. Sci Rep. 2022;12:14772. doi: 10.1038/s41598-022-18996-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-18996-x</ArticleId><ArticleId IdType="pmc">PMC9427088</ArticleId><ArticleId IdType="pubmed">36042275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammitzb&#xf8;ll C, Bartels LE, B&#xf8;gh Andersen J, et al. Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol. 2021;3:622&#x2013;628. doi: 10.1002/acr2.11299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11299</ArticleId><ArticleId IdType="pmc">PMC8426741</ArticleId><ArticleId IdType="pubmed">34273260</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Thomas &#x39a;, Grigoropoulos I, Alexopoulou P, et al. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2. Rheumatology. 2023; 10.1093/rheumatology/kead236. This study descibes cell-mediated immune responses as a vaccination efficacy marker against SARS-CoV-2 in RTX-treated patients</Citation><ArticleIdList><ArticleId IdType="pubmed">37228039</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Petri M, Joyce D, Haag K, Fava A, Goldman DW, Zhong D, Xiao S, Milstone A, Magder LS. Effect of systemic lupus erythematosus and immunosuppressive agents on COVID-19 vaccination antibody response. Arthritis Care Res. 2023; 10.1002/acr.25094. SLE patients, regardless of immunosuppressive therapy, have lower vaccine IgG levels compared to healthy control group</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10387122</ArticleId><ArticleId IdType="pubmed">36714913</ArticleId></ArticleIdList></Reference><Reference><Citation>Speer C, T&#xf6;llner M, Benning L, et al. Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2022;81:593&#x2013;595. doi: 10.1136/annrheumdis-2021-221747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221747</ArticleId><ArticleId IdType="pubmed">35012926</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieske L, van Dam KPJ, Steenhuis M, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022;4:e338&#x2013;e350. doi: 10.1016/S2665-9913(22)00034-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00034-0</ArticleId><ArticleId IdType="pmc">PMC8930018</ArticleId><ArticleId IdType="pubmed">35317410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak D, Simader E, Sieghart D, et al. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. Ann Rheum Dis. 2022;81:1750&#x2013;1756. doi: 10.1136/ard-2022-222579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222579</ArticleId><ArticleId IdType="pubmed">35977809</ArticleId></ArticleIdList></Reference><Reference><Citation>Troldborg A, Thomsen MK, Bartels LE, et al. Time since rituximab treatment is essential for developing a humoral response to COVID-19 mRNA vaccines in patients with rheumatic diseases. J Rheumatol. 2022;49:644&#x2013;649. doi: 10.3899/jrheum.211152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.211152</ArticleId><ArticleId IdType="pubmed">35232803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitoun S, Henry J, Desjardins D, et al. Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis &amp; Rheumatology. 2022;74:927&#x2013;933. doi: 10.1002/art.42058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42058</ArticleId><ArticleId IdType="pmc">PMC9011892</ArticleId><ArticleId IdType="pubmed">34962357</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23:186&#x2013;193. doi: 10.1038/s41590-021-01122-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Boedecker-Lips SC, Cla&#xdf;en P, Kraus D, Weinmann-Menke J. Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus. Rheumatology. 2023;62:e34&#x2013;e35. doi: 10.1093/rheumatology/keac459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac459</ArticleId><ArticleId IdType="pmc">PMC9384795</ArticleId><ArticleId IdType="pubmed">35972412</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabris M, De Marchi G, Domenis R, et al. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. J Autoimmun. 2022; 10.1016/j.jaut.2022.102827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995326</ArticleId><ArticleId IdType="pubmed">35427999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattui SE, Liew JW, Kennedy K, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021;7:e001814. doi: 10.1136/rmdopen-2021-001814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001814</ArticleId><ArticleId IdType="pmc">PMC8424419</ArticleId><ArticleId IdType="pubmed">34493645</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022;81:695&#x2013;709. doi: 10.1136/annrheumdis-2021-221490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221490</ArticleId><ArticleId IdType="pubmed">34972811</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslak F, Gunalp A, Cebi MN, Yildiz M, Adrovic A, Sahin S, Barut K, Kasapcopur O. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study. Int J Rheum Dis. 2022;25:353&#x2013;363. doi: 10.1111/1756-185X.14279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14279</ArticleId><ArticleId IdType="pubmed">34978376</ArticleId></ArticleIdList></Reference><Reference><Citation>So H, Li T, Chan V, Tam LS, Chan PKS. Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2022; 10.1177/1759720X221089586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021484</ArticleId><ArticleId IdType="pubmed">35464809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Li F, Tian J, Kang J, He J. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey. Clin Exp Med. 2022; 10.1007/s10238-022-00832-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9130966</ArticleId><ArticleId IdType="pubmed">35612692</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornaro M, Venerito V, Iannone F, Cacciapaglia F. Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-CoV-2 vaccination in patients with rare rheumatic diseases. Journal of Rheumatology. 2022;49:334&#x2013;335. doi: 10.3899/jrheum.210863.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.210863</ArticleId><ArticleId IdType="pubmed">35033998</ArticleId></ArticleIdList></Reference><Reference><Citation>Assawasaksakul T, Lertussavavivat T, Sathitratanacheewin S, et al. Comparison of immunogenicity and safety of inactivated, adenovirus-vectored, and heterologous adenovirus-vectored/mRNA vaccines in patients with systemic lupus erythematosus and rheumatoid arthritis: a prospective cohort study. Vaccines. 2022; 10.3390/vaccines10060853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9227480</ArticleId><ArticleId IdType="pubmed">35746461</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveen R, Nikiphorou E, Joshi M, et al. Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. Rheumatology. 2022; 10.1093/rheumatology/keac661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10321116</ArticleId><ArticleId IdType="pubmed">36413073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Gasparyan AY, Zimba O, Kitas GD. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. Clin Rheumatol. 2022;41:2893&#x2013;2910. doi: 10.1007/s10067-022-06227-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06227-7</ArticleId><ArticleId IdType="pmc">PMC9152659</ArticleId><ArticleId IdType="pubmed">35639259</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavala-Flores E, Salcedo-Matienzo J, Quiroz-Alva A, Berrocal-Kasay A. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol. 2022;41:1349&#x2013;1357. doi: 10.1007/s10067-021-05980-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05980-5</ArticleId><ArticleId IdType="pmc">PMC8592807</ArticleId><ArticleId IdType="pubmed">34782941</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekel L, Kummer LY, van Dam KPJ, et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol. 2021;3:e542&#x2013;e545. doi: 10.1016/S2665-9913(21)00181-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00181-8</ArticleId><ArticleId IdType="pmc">PMC8213359</ArticleId><ArticleId IdType="pubmed">34179831</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerosa M, Schioppo T, Argolini LM, et al. The impact of anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: a multicentre cohort study. Vaccines. 2022; 10.3390/vaccines10050663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146432</ArticleId><ArticleId IdType="pubmed">35632419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Ni J, Chu Y-Y, et al. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis. Biomedicine &amp; Pharmacotherapy. 2022;150:112997. doi: 10.1016/j.biopha.2022.112997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.112997</ArticleId><ArticleId IdType="pmc">PMC9040458</ArticleId><ArticleId IdType="pubmed">35486976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri C, Ursini F, Gragnani L, et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients&#x2019; subgroups. J Autoimmun. 2021; 10.1016/j.jaut.2021.102744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577991</ArticleId><ArticleId IdType="pubmed">34781162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels LE, Ammitzb&#xf8;ll C, Andersen JB, et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2021;41:1925&#x2013;1931. doi: 10.1007/s00296-021-04972-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04972-7</ArticleId><ArticleId IdType="pmc">PMC8412379</ArticleId><ArticleId IdType="pubmed">34476603</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya M, Levine JM, Siegel CH, Bykerk VP, Jannat-Khah D, Mandl LA. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol. 2022;41:1619&#x2013;1622. doi: 10.1007/s10067-021-05963-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05963-6</ArticleId><ArticleId IdType="pmc">PMC8556788</ArticleId><ArticleId IdType="pubmed">34716843</ArticleId></ArticleIdList></Reference><Reference><Citation>Chehab G, Richter JG, Brinks R, Fischer-Betz R, Winkler-Rohlfing B, Schneider M. Vaccination coverage in systemic lupus erythematosus&#x2014;a cross-sectional analysis of the German long-term study (LuLa cohort) Rheumatology. 2018;57:1439&#x2013;1447. doi: 10.1093/rheumatology/key120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key120</ArticleId><ArticleId IdType="pubmed">29757414</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Planas D, Ouedrani A, et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis. 2022; 10.1136/annrheumdis-2021-221508.</Citation><ArticleIdList><ArticleId IdType="pubmed">35022159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tien N, Chang YC, Chen PK, Lin HJ, Chang SH, Lan JL, Hsueh PR, Chang CK, Chen DY. The immunogenicity and safety of three types of SARS-CoV-2 vaccines in adult patients with immune-mediated inflammatory diseases: a longitudinal cohort study. Biomedicines. 2022; 10.3390/biomedicines10040911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9025718</ArticleId><ArticleId IdType="pubmed">35453660</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Mel&#xe9;ndez A, B&#xe1;ez-Negr&#xf3;n L, R&#xed;os-Rivera R, Franco-O&#x2019;Connell AS, Nieves-Plaza M, Vil&#xe1; LM. Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: a cohort study from Puerto Rico. Lupus. 2023; 10.1177/09612033231151898.</Citation><ArticleIdList><ArticleId IdType="pubmed">36639887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T, Tsuji H, Onishi A, et al. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. Lupus Sci Med. 2022; 10.1136/lupus-2022-000727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9378947</ArticleId><ArticleId IdType="pubmed">35961691</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil S, Patil A. Systemic lupus erythematosus after COVID-19 vaccination: a case report. J Cosmet Dermatol. 2021;20:3103&#x2013;3104. doi: 10.1111/jocd.14386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocd.14386</ArticleId><ArticleId IdType="pmc">PMC8661983</ArticleId><ArticleId IdType="pubmed">34418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Zengarini C, Pileri A, Salamone FP, Piraccini BM, Vitale G, La Placa M. Subacute cutaneous lupus erythematosus induction after SARS-CoV-2 vaccine in a patient with primary biliary cholangitis. Journal of the European Academy of Dermatology and Venereology. 2022;36:e179&#x2013;e180. doi: 10.1111/jdv.17827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17827</ArticleId><ArticleId IdType="pmc">PMC9011449</ArticleId><ArticleId IdType="pubmed">34807495</ArticleId></ArticleIdList></Reference><Reference><Citation>Nune A, Iyengar KP, Ish P, Varupula B, Musat CA, Sapkota HR. The emergence of new-onset SLE following SARS-CoV-2 vaccination. QJM: an International Journal of Medicine. 2021;114:739&#x2013;740. doi: 10.1093/qjmed/hcab229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab229</ArticleId><ArticleId IdType="pubmed">34450645</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina-Rios S, Rojas-Martinez R, Est&#xe9;vez-Ramirez GM, Medina YF, Molina-Rios S, Rojas-Martinez R, Marcela Est&#xe9;vez-Ramirez G, Medina YF, Rios SM. Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report. Mod Rheumatol Case Rep. 2023;7:43&#x2013;46. doi: 10.1093/mrcr/rxac018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mrcr/rxac018</ArticleId><ArticleId IdType="pmc">PMC8903504</ArticleId><ArticleId IdType="pubmed">35246682</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrashdi Mousa N, Saleh AM, Khalid A, Alshaya AK, Alanazi SMM. Systemic lupus erythematosus with acute pancreatitis and vasculitic rash following COVID-19 vaccine: a case report and literature review. Clin Rheumatol. 2022;41:1577&#x2013;1582. doi: 10.1007/s10067-022-06097-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06097-z</ArticleId><ArticleId IdType="pmc">PMC8852987</ArticleId><ArticleId IdType="pubmed">35175446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavala-Miranda MF, Gonz&#xe1;lez-Ibarra SG, P&#xe9;rez-Arias AA, Uribe-Uribe NO, Mejia-Vilet JM. New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination. Kidney Int. 2021;100:1340&#x2013;1341. doi: 10.1016/j.kint.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8455236</ArticleId><ArticleId IdType="pubmed">34560139</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe1;ez-Negr&#xf3;n L, Vil&#xe1; LM. New-onset systemic lupus erythematosus after mRNA SARS-CoV-2 vaccination. Case Rep Rheumatol. 2022;2022:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8856802</ArticleId><ArticleId IdType="pubmed">35186342</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidaka D, Ogasawara R, Sugimura S, et al. New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination. Int J Hematol. 2022;115:424&#x2013;427. doi: 10.1007/s12185-021-03243-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-021-03243-2</ArticleId><ArticleId IdType="pmc">PMC8536917</ArticleId><ArticleId IdType="pubmed">34687421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur I, Zafar S, Capitle E, Khianey R. COVID-19 vaccination as a potential trigger for new-onset systemic lupus erythematosus. Cureus. 2022; 10.7759/cureus.21917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901143</ArticleId><ArticleId IdType="pubmed">35273863</ArticleId></ArticleIdList></Reference><Reference><Citation>Raviv Y, Betesh-Abay B, Valdman-Grinshpoun Y, Boehm-Cohen L, Kassirer M, Sagy I. First presentation of systemic lupus erythematosus in a 24-year-old male following mRNA COVID-19 vaccine. Case Rep Rheumatol. 2022;2022:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825270</ArticleId><ArticleId IdType="pubmed">35154842</ArticleId></ArticleIdList></Reference><Reference><Citation>Remmel A. Why is it so hard to investigate the rare side effects of COVID vaccines? Nature. 2021; 10.1038/d41586-021-00880-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33795861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CCJ. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine. 2023; 10.1016/j.eclinm.2022.101783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830133</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Alarc&#xf3;n GS, Izadi Z, et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Ann Rheum Dis. 2022;81:970&#x2013;978. doi: 10.1136/annrheumdis-2021-221636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221636</ArticleId><ArticleId IdType="pmc">PMC8882632</ArticleId><ArticleId IdType="pubmed">35172961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordtz R, Kristensen S, Dalgaard LPH, Westermann R, Duch K, Lindhardsen J, Torp-Pedersen C, Dreyer L. Incidence of covid-19 hospitalisation in patients with systemic lupus erythematosus: a nationwide cohort study from denmark. J Clin Med. 2021; 10.3390/JCM10173842/S1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8432052</ArticleId><ArticleId IdType="pubmed">34501290</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruera S, Lei X, Zhao H, Yazdany J, Chavez-MacGregor M, Giordano SH, Suarez-Almazor ME. Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus. Lupus Sci Med. 2023;10:e000750. doi: 10.1136/lupus-2022-000750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000750</ArticleId><ArticleId IdType="pmc">PMC9929928</ArticleId><ArticleId IdType="pubmed">36787921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Alarc&#xf3;n GS, Seet AM, et al. Association between race/ethnicity and COVID-19 outcomes in systemic lupus erythematosus patients from the United States: data from the COVID-19 Global Rheumatology Alliance. Arthritis Care Res. 2023;75:53&#x2013;60. doi: 10.1002/acr.25039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.25039</ArticleId><ArticleId IdType="pmc">PMC9874592</ArticleId><ArticleId IdType="pubmed">36239292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised patients with protracted COVID-19: a review of &#x201c;long persisters&#x201d;. Curr Transplant Rep. 2022;9:209&#x2013;218. doi: 10.1007/s40472-022-00385-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40472-022-00385-y</ArticleId><ArticleId IdType="pmc">PMC9660019</ArticleId><ArticleId IdType="pubmed">36407883</ArticleId></ArticleIdList></Reference><Reference><Citation>Notz Q, Meybohm P, Kranke P, Weismann D, Lotz C, Schmalzing M. Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on &#x2018;Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine&#x2019; by Mathian et al. Ann Rheum Dis. 2022;81:e216. doi: 10.1136/annrheumdis-2020-218778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218778</ArticleId><ArticleId IdType="pubmed">32859609</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutinho-Pereira S, Calisto R, Sabio F, Guerreiro L. High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection. BMJ Case Rep. 2021;14:e244853. doi: 10.1136/bcr-2021-244853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-244853</ArticleId><ArticleId IdType="pmc">PMC8388267</ArticleId><ArticleId IdType="pubmed">34433539</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291&#x2013;2293. doi: 10.1056/NEJMc2031364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Strangfeld A, Sch&#xe4;fer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80:930&#x2013;942. doi: 10.1136/annrheumdis-2020-219498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219498</ArticleId><ArticleId IdType="pmc">PMC7843211</ArticleId><ArticleId IdType="pubmed">33504483</ArticleId></ArticleIdList></Reference><Reference><Citation>Obri&#x219;c&#x103; B, Vornicu A, Jurubi&#x21b;&#x103; R, et al. Characteristics of SARS-CoV-2 infection in an actively monitored cohort of patients with lupus nephritis. Biomedicines. 2022;10:2423. doi: 10.3390/biomedicines10102423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10102423</ArticleId><ArticleId IdType="pmc">PMC9599215</ArticleId><ArticleId IdType="pubmed">36289685</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemente D, Udaondo C, de Inocencio J, et al. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases. Pediatr Rheumatol Online J. 2021;19:162. doi: 10.1186/s12969-021-00648-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-021-00648-5</ArticleId><ArticleId IdType="pmc">PMC8626725</ArticleId><ArticleId IdType="pubmed">34838054</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters HM, Mian Z, Thomas L, Cerise J, Eberhard BA, Pagano E, Gottlieb BS, Steigerwald K, Hui-Yuen JS. Seroprevalence and clinical outcomes of SARS-CoV-2 in paediatric patients with rheumatic disease. Rheumatology. 2022;61:SI112&#x2013;SI119. doi: 10.1093/rheumatology/keab730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab730</ArticleId><ArticleId IdType="pubmed">34599820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal P, Goyal A, Cusick A, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53:117&#x2013;134. doi: 10.1080/07853890.2020.1839959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2020.1839959</ArticleId><ArticleId IdType="pmc">PMC7880079</ArticleId><ArticleId IdType="pubmed">33095083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, Pavel MA, Wang H, Kwachukwu JC, Mediouni S, Jablonski JA, Nettles KW, Reddy CB, Valente ST, Hansen SB. Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture. Commun Biol. 2022;5:958. doi: 10.1038/s42003-022-03841-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03841-8</ArticleId><ArticleId IdType="pmc">PMC9472185</ArticleId><ArticleId IdType="pubmed">36104427</ArticleId></ArticleIdList></Reference><Reference><Citation>Boralli VB. COVID-19 pandemic&#x2014;a narrative review of the potential roles of chloroquine and hydroxychloroquine. Pain Physician. 2020;4S(23):S351&#x2013;S366. doi: 10.36076/ppj.2020/23/S351.</Citation><ArticleIdList><ArticleId IdType="doi">10.36076/ppj.2020/23/S351</ArticleId><ArticleId IdType="pubmed">32942793</ArticleId></ArticleIdList></Reference><Reference><Citation>Walbi IA, Albarqi HA, Alghanim NS, et al. Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. Journal of International Medical Research. 2022;50:030006052210903. doi: 10.1177/03000605221090363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605221090363</ArticleId><ArticleId IdType="pmc">PMC8998490</ArticleId><ArticleId IdType="pubmed">35387504</ArticleId></ArticleIdList></Reference><Reference><Citation>Oztas M, Bektas M, Karacan I, et al. Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine. J Med Virol. 2022;94:3431&#x2013;3437. doi: 10.1002/jmv.27731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27731</ArticleId><ArticleId IdType="pmc">PMC9088463</ArticleId><ArticleId IdType="pubmed">35315100</ArticleId></ArticleIdList></Reference><Reference><Citation>Pileggi GS, Ferreira GA, Reis APMG, et al. Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. Advances in Rheumatology. 2021;61:60. doi: 10.1186/s42358-021-00217-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-021-00217-0</ArticleId><ArticleId IdType="pmc">PMC8496137</ArticleId><ArticleId IdType="pubmed">34620246</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S-Y, Kim M-S, Kim M-C, Choi S-H, Chung J-W, Choi ST. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. Clinical Microbiology and Infection. 2021;27:611&#x2013;617. doi: 10.1016/j.cmi.2020.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.12.003</ArticleId><ArticleId IdType="pmc">PMC7832641</ArticleId><ArticleId IdType="pubmed">33316402</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso S, Spinelli FR, Agati L, et al. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2021;40:890&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">35383554</ArticleId></ArticleIdList></Reference><Reference><Citation>Belmont HM, Haj-Ali M. Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine-treated systemic lupus erythematosus patients. Rheumatology. 2022;62:450&#x2013;456. doi: 10.1093/rheumatology/keac245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac245</ArticleId><ArticleId IdType="pmc">PMC9383788</ArticleId><ArticleId IdType="pubmed">35426919</ArticleId></ArticleIdList></Reference><Reference><Citation>Park E, Giles JT, Perez-Recio T, Pina P, Depender C, Gartshteyn Y, Askanase AD, Bathon J, Geraldino-Pardilla L. Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients. Arthritis Res Ther. 2021;23:271. doi: 10.1186/s13075-021-02646-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02646-0</ArticleId><ArticleId IdType="pmc">PMC8554185</ArticleId><ArticleId IdType="pubmed">34715924</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859&#x2013;866. doi: 10.1136/annrheumdis-2020-217871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho JS, dos Reis Neto ET, Kakehasi AM, et al. Factors associated with poor outcomes in SLE patients with COVID-19: Data from ReumaCoV-Brazil register. Lupus. 2023;32:42&#x2013;53. doi: 10.1177/09612033221135884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221135884</ArticleId><ArticleId IdType="pmc">PMC9614598</ArticleId><ArticleId IdType="pubmed">36300790</ArticleId></ArticleIdList></Reference><Reference><Citation>Montero F, Mart&#xed;nez-Barrio J, Serrano-Benavente B, Gonz&#xe1;lez T, Rivera J, Molina Collada J, Castrej&#xf3;n I, &#xc1;lvaro-Gracia J. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40:1593&#x2013;1598. doi: 10.1007/s00296-020-04676-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04676-4</ArticleId><ArticleId IdType="pmc">PMC7425254</ArticleId><ArticleId IdType="pubmed">32794113</ArticleId></ArticleIdList></Reference><Reference><Citation>Landew&#xe9; RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.&#xa0;Ann Rheum dis. 2022;81(12):1628&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">35197264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez GA, Argolini LM, Bellocchi C, et al. Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. Clinical Immunology. 2021;231:108845. doi: 10.1016/j.clim.2021.108845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108845</ArticleId><ArticleId IdType="pmc">PMC8405598</ArticleId><ArticleId IdType="pubmed">34478882</ArticleId></ArticleIdList></Reference><Reference><Citation>Favalli EG, Gerosa M, Murgo A, Caporali R. Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis. 2021;80:e25. doi: 10.1136/annrheumdis-2020-217787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217787</ArticleId><ArticleId IdType="pubmed">32451344</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques CDL, Kakehasi AM, Pinheiro MM, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open. 2021;7:e001461. doi: 10.1136/rmdopen-2020-001461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001461</ArticleId><ArticleId IdType="pmc">PMC7844930</ArticleId><ArticleId IdType="pubmed">33510041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendebien Z, von Frenckell C, Ribbens C, Andr&#xe9; B, Thys M, Gangolf M, Seidel L, Malaise MG, Malaise O. Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments. Ann Rheum Dis. 2021;80:e94. doi: 10.1136/annrheumdis-2020-218244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218244</ArticleId><ArticleId IdType="pubmed">32586921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahebari M, Mirfeizi Z, Hashemzadeh K, Nik ES, Shamkani NG. Effects of biologic therapies on the chance of COVID-19 infection among rheumatoid arthritis and lupus patients during the first wave of the pandemic. Arch Bone Jt Surg. 2022;10:946&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749122</ArticleId><ArticleId IdType="pubmed">36561225</ArticleId></ArticleIdList></Reference><Reference><Citation>Notz Q, Meybohm P, Kranke P, Weismann D, Lotz C, Schmalzing M. Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on &#x2018;Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine&#x2019; by Mathi. Ann Rheum Dis. 2022;81:e216. doi: 10.1136/annrheumdis-2020-218778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218778</ArticleId><ArticleId IdType="pubmed">32859609</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R, Duret P-M, Bauer E, et al. B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. Ann Rheum Dis. 2022;81:143&#x2013;145. doi: 10.1136/annrheumdis-2021-220549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220549</ArticleId><ArticleId IdType="pubmed">34556483</ArticleId></ArticleIdList></Reference><Reference><Citation>Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3:e419&#x2013;e426. doi: 10.1016/S2665-9913(21)00059-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00059-X</ArticleId><ArticleId IdType="pmc">PMC7993930</ArticleId><ArticleId IdType="pubmed">33786454</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97:E1870&#x2013;E1885. doi: 10.1212/WNL.0000000000012753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012753</ArticleId><ArticleId IdType="pmc">PMC8601210</ArticleId><ArticleId IdType="pubmed">34610987</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol. 2022;4:e33&#x2013;e41. doi: 10.1016/S2665-9913(21)00325-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00325-8</ArticleId><ArticleId IdType="pmc">PMC8592562</ArticleId><ArticleId IdType="pubmed">34806036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachiller-Corral J, Boteanu A, Garcia-Villanueva MJ, et al. Risk of severe COVID-19 infection in patients with inflammatory rheumatic diseases. J Rheumatol. 2021;48:1098&#x2013;1102. doi: 10.3899/jrheum.200755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200755</ArticleId><ArticleId IdType="pubmed">33722949</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2022;4:e177&#x2013;e187. doi: 10.1016/S2665-9913(21)00394-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00394-5</ArticleId><ArticleId IdType="pmc">PMC8700278</ArticleId><ArticleId IdType="pubmed">34977602</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekel L, Wolbink GJ. Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. Lancet Rheumatol. 2022;4:e154&#x2013;e155. doi: 10.1016/S2665-9913(21)00418-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00418-5</ArticleId><ArticleId IdType="pmc">PMC8700274</ArticleId><ArticleId IdType="pubmed">34977601</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab&#x2013;cilgavimab) for prevention of Covid-19. New England Journal of Medicine. 2022;386:2188&#x2013;2200. doi: 10.1056/NEJMoa2116620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116620</ArticleId><ArticleId IdType="pmc">PMC9069994</ArticleId><ArticleId IdType="pubmed">35443106</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Haste N, Binkin N, Law N, Horton LE, Yam N, Chen V, Abeles S. Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era. PLoS One. 2023;18:e0275356. doi: 10.1371/journal.pone.0275356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0275356</ArticleId><ArticleId IdType="pmc">PMC10138227</ArticleId><ArticleId IdType="pubmed">37104498</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese C, Kirchner E, Villa-Forte A, Hajj-Ali RA, Moss BP, Fernandez JP, Calabrese L. Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. RMD Open. 2022; 10.1136/rmdopen-2022-002557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9485640</ArticleId><ArticleId IdType="pubmed">36123015</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.covid19treatmentguidelines.nih.gov/overview/prevention-of-sars-cov-2. Accessed&#xa0;15 Jun 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>